Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.79 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 2/20 | 0.37 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.35 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.33 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.33 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.33 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.33 |
| ▸ | GALR3 | O60755 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | BLM | P54132 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.32 |
| ▸ | PGD | P52209 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7149904 | 1.00 | TDP1 (0.79) | TDP1ABCB1POLBMAPK1TSHR | |
| SCHEMBL7153751 | 1.00 | TDP1 (0.79) | TDP1ABCB1POLBMAPK1TSHR | |
| SCHEMBL7154920 | 1.00 | TDP1 (0.79) | TDP1ABCB1POLBMAPK1TSHR | |
| SCHEMBL23720379 | 0.98 | TDP1 (0.82) | TDP1ABCB1POLBMAPK1TSHR | |
| SCHEMBL21544876 | 0.91 | TDP1 (0.71) | TDP1ABCB1POLBMAPK1TSHR | |
| SCHEMBL27754500 | 0.91 | TDP1 (0.66) | TDP1ABCB1POLBMAPK1TSHR | |
| SCHEMBL826717 | 0.90 | TDP1 (0.96) | TDP1ABCB1POLBMAPK1TSHR | |
| SCHEMBL2175855 | 0.90 | TDP1 (0.96) | TDP1ABCB1POLBMAPK1TSHR | |
| SCHEMBL270042 | 0.90 | TDP1 (0.96) | TDP1ABCB1POLBMAPK1TSHR | |
| SCHEMBL7149374 | 0.90 | TDP1 (0.96) | TDP1ABCB1POLBMAPK1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11591416-B2 | Exopolysaccharides and uses thereof | SOFAR S.P.A. (IT) | 2023-02-28 | — | — | US | claimed |
| US-20190345268-A1 | EXOPOLYSACCHARIDES AND USES THEREOF | ALFASIGMA S.P.A. (IT) | 2019-11-14 | — | — | US | claimed |
| US-11591416-B2 | Exopolysaccharides and uses thereof | SOFAR S.P.A. (IT) | 2023-02-28 | — | — | US | disclosed |
| US-11407768-B2 | AMPK activators | KALLYOPE, INC. (US) | 2022-08-09 | — | — | US | disclosed |
| EP-3978488-A1 | ZINC CHELATING COMPOUNDS FOR USE IN THE TREATMENT OF BACTERIAL INFECTION | Universitetet I Oslo (NO) | 2022-04-06 | — | — | EP | disclosed |
| US-20190345268-A1 | EXOPOLYSACCHARIDES AND USES THEREOF | ALFASIGMA S.P.A. (IT) | 2019-11-14 | — | — | US | disclosed |
| US-8540966-B2 | Contrast agents endowed with high relaxivity | BRACCO IMAGING S.P.A. (IT) | 2013-09-24 | — | — | US | disclosed |
| US-20110256067-A1 | Contrast agents endowed with high relaxivity | BRACCO IMAGING SPA (IT) | 2011-10-20 | — | — | US | disclosed |
| US-7732625-B2 | Colorant compounds | XEROX CORPORATION (US) | 2010-06-08 | — | — | US | disclosed |
| US-7311767-B2 | Forming a salt of a liquid phase change ink carrier of stearyl stearamide, an amine substituted Xanthene, acridine, anthracene or thioxanthene chromogen, and a metal salt capable of forming a compound with two chromogens | XEROX CORPORATION (US) | 2007-12-25 | — | — | US | disclosed |
| US-7301025-B2 | N-(2-(2-(alkyl[carbamoyl, carbonyloxy or ureido]alkyl)pyridinium)-5-(carboxy or sulfo)phenyl-8-((2-(N-alkyl[carbamoyl or ureido]alkyl)pyridinyl) xanthene ligands complexed with a metal or metal-containing moiety; magenta dye with improved heat resistance; hot melts or phase change inks | XEROX CORPORATION (US) | 2007-11-27 | — | — | US | disclosed |
| US-7176317-B2 | Colorant compounds | XEROX CORPORATION (US) | 2007-02-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110256067-A1 | Contrast agents endowed with high relaxivity | SLC40A1, SLC67A1, SLC19A1 | TDP1 1664/4885ABCB1 1017/4885POLB 2289/4885 |
| US-11591416-B2 | Exopolysaccharides and uses thereof | TLR5, TLR3, TLR2 | TDP1 3938/4885ABCB1 4419/4885POLB 4212/4885 |
| US-11407768-B2 | AMPK activators | PRKAG1, PRKAG2, PRKAA1 | TDP1 3084/4885ABCB1 4425/4885POLB 3399/4885 |
| US-20190345268-A1 | EXOPOLYSACCHARIDES AND USES THEREOF | TLR5, TLR3, TLR2 | TDP1 3938/4885ABCB1 4419/4885POLB 4212/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.